**New drug information**

- **Symproic™ (naldemedine):** The Food and Drug Administration (FDA) approved Shionogi Inc. and Purdue Pharma L.P.’s Symproic for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Because it is structurally similar to naltrexone, it is a Schedule II controlled substance. Shinonogi Inc. has submitted a petition to remove the controlled substance classification to the U.S. Drug Enforcement Administration (DEA). The launch of Symproic is scheduled for the summer of 2017.

**New generics**

- **Zyflo CR® (zileuton extended-release):** Rising Pharmaceuticals has launched the first generic of Chiesi USA’s Zyflo CR for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

- **Venlafaxine ER® (venlafaxine extended-release [ER]):** Nostrum Laboratories has launched the first true generic of UCB Pharma and Vertical Pharmaceutical’s Venlafaxine ER 24-hour tablet for the treatment of major depressive disorder and social anxiety disorder.

- **Quartette® (levonorgestrel/ethinyl estradiol):** Lupin Pharmaceuticals has launched the first generic of Teva’s Quartette for pregnancy prevention.

- **Tazorac® (tazarotene):** Greenstone has launched the first generic for Allergan’s Tazorac cream for the topical treatment of patients with plaque psoriasis and for the topical treatment of patients with acne vulgaris.

While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner.